UPDATE: Citigroup Reiterates on Endo Health Solutions on Potential of Paladin Acquisition

Loading...
Loading...
In a report published Tuesday, Citigroup analyst Liav Abraham reiterated a Buy rating on
Endo Health SolutionsENDP
, and raised the price target from $43.00 to $70.00. In the report, Citigroup noted, “We view Endo's proposed acquisition of Paladin as a highly strategic, innovative deal that: (i) augments the company's international presence in the specialty pharmaceuticals arena; (ii) improves cash flow generation, thereby strengthening Endo's balance sheet; and (iii) provides the company with an Irish domicile and an attractive tax rate, increasing the attractiveness of potential future acquisitions and enhancing the scope for M&A activities. We maintain our Buy rating.” Endo Health Solutions closed on Monday at $61.86.
Posted In: Analyst ColorPrice TargetAnalyst RatingsCitigroupLiav Abraham
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...